- Total Pro Portfolios with AMLN:
- Buffalo Science & Technology BUFTX
- Columbia Marsico 21st Century Z (NMYAX)
- Farallon Capital Management LLC
- Buffalo Mid Cap - BUFMX
- show more
- Total Do-It-Yourself Portfolios with AMLN:
- milton
- Northwoods
- Franz Portfolio 1
- H.F. Enger Portfolio 1
- 401k pep
- David Thursz Portfolio 1
- P J Rosen Portfolio 1
- healthcare / biotech
- check
- some energy etc
- david g martin Portfolio 1
- Banking on it!
- arnold holtzman Portfolio 1
- PRIMARY1
- mevameva Portfolio 1
- Hiten
- Yogi bear Portfolio 1
- TPG - The Prayer Group ( Investment Club)
- hwalk Portfolio 1
- SUPRATRADE-QUANTUM STARDUST 7
- SUPRATRADE FRIDAY SUN 1304071836
- happyjack Portfolio 1
- beit07 Portfolio 1
- SUPRATRADE VIRTUAL VI
- Bill's IRARetirement in 5 years
- rmdst3000 Portfolio 1
- hdunzinger Portfolio 1
- mstover1 Portfolio 1
- Jeffsdsu Portfolio 1
- Chart Screening
- 401K unit
- BENITRANS BL
- fasteddie5439 Portfolio 1
- bigmo
- jerk
- ESCAPE
- samp1 Portfolio 1
- tom78759 Portfolio 1
- SUPRATRADE 3007071748
- Aug0107
- rv's
- Surviving Stocks after Market Correction (above 50 day moving average): August 15, 2007
- bjb3013 Portfolio 1
- brokedude
- jake726 Portfolio 1
- wishing & hoping
- FBSPANKEY Portfolio 1
- jheath Portfolio 1
- TAI Port
- PART 1 JPMorgan 26th Annual Healthcare Conf 1/7/08..1st Day Reporting Companies..Nymph Take
- Wild Bill's Future
- show more
- 118
- Boynton
- 83Northwoods
- king skagg
- Jin Blue Portfolio 1
- aajjss Portfolio 1
- PC Current
- John P Smith Portfolio 1
- Ort2
- tjeccleburg Portfolio 1
- Dave Kumar Portfolio 1
- Portfolio Two
- Fvicks Portfolio 1
- Cole Main Portfolio
- boomergroup
- sandy dandy
- zillmear Portfolio 1
- Ameritrade Joint Acct.
- Mary's Old 401K
- bluegrayman Portfolio 1
- 9lives Portfolio 1
- Medusa
- jchimaru Portfolio 1
- ler#1
- Jimijazz-Balanced
- ched9999 Portfolio 1
- davidpsl Portfolio 1
- SMID Growth A
- frwayne Portfolio 1
- RCD01
- awaveman Bios
- Cleveland Portfolio
- scjs4r speculative
- giiljs Portfolio 1
- dabish09-Roth IRA
- bigespicks
- RICKMEILS Portfolio 1
- HARVEEE1000 Portfolio 1
- wzander Portfolio 1
- mgbinsd
- SUPRATRADE " BUY IT ALL NOW"!! 0408070235(august 4)
- SUPRATRADE "BUY IT ALL TODAY " 0909071845(9.august)
- nardonem Portfolio 1
- canuck7699 Portfolio 1
- bsnell Portfolio 1
- ds3145
- Debbie Z
- BENITRANS FZ
- ralphmalph Portfolio 1
- Highfives
- Fast Money's Bear Buy List
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:barrons3 |
Date:05 16 09 |
Both Carl Icahn and Eastbourne Capital had nominated five directors to the company's 12-person board. However, the election of a majority of new directors would constitute a change of control under the company's debt agreements, resulting in a default. To prevent this possibility, Icahn and Eastbourne (although not acting as a group) received no-action relief from the Securities and Exchange Commission, allowing them to amend their proxies so that each would effectively include the same two Icahn nominees, three Eastbourne nominees and seven incumbent directors. |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:04 22 09 |
Also I’m keeping an eye on Amylin (AMLN). - Pete Najarian |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:01 31 09 |
Carl Icahn intends to commence a proxy fight to elect five directors to the company's 12-person board. |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:01 07 09 |
Takeover targets are wide ranging and include Biogen [BIIB], Amylin (AMLN), OSI Pharma [OSIP], and Vertex Pharma [VRTX], says Huckman. |
|
Not yet rated
Rate now:
|
|
By:sarah z |
Date:10 24 08 |
From a recent Mad Money show: "Oh, way too speculative. No thank you. I've got biotechs of incredible quality delivering great numbers and going nowhere. How can I recommend this one?" |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:09 20 08 |
Carl Icahn has increased his stake to 7.33% (10.06 million shares) from 6.54%. |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:08 16 08 |
Another company that could spark an acquirer's interest is Amylin Pharmaceuticals (AMLN). It's working on a Type 2 diabetes drug that could be injected once a week instead of daily. Amylin has several development partners, including Eli Lilly, on the drug. It already markets two diabetes drugs, Symlin and Byetta. But some analysts say the product under development could boast major advantages. "A once-weekly drug that lowers glucose substantially, induces weight loss, isn't associated with hypoglycemia, and lacks a cardiovascular safety signal has multibillion-dollar potential," says Markowitz. |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:08 06 08 |
News of the Bristol-Meyers (BMY) offer to buy out ImClone (IMCL) deal triggered a flurry of option activity in Amgen (AMGN), |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Amylin Pharmaceuticals (AMLN) downgraded at Jefferies. Rating lowered to Hold from Buy. Price target lowered to $33 from $47. 2008 EPS estimates maintained at -$2.08. |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:05 31 08 |
Carl Icahn said he recently had discussions with AMLN management and may seek to do so again on ideas to enhance shareholder value (for more, see Spotlight at right). Icahn believes AMLN stock is undervalued; he and his affiliates beneficially own 8.96 million shares (6.54%), including about 2.17 million underlying call options, which expire on March 10, 2010. |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
By:Brian Walsh |
Date:01 03 07 |
valuation |
|
Not yet rated
Rate now:
|
|








